21st Century Cures Act — Beau Biden Cancer Moonshot — CFDA 93.353

Moonshot obligations at $839,069,334.40

USAspending.gov records $839,069,334.40 in obligations under CFDA 93.353. One hundred sixty-eight awards produce that stock. A simple average is about $4,994,460 per award. That average is a quotient of two packet totals, not a typical NIH project budget and not a cost per trial arm. Other National Cancer Institute listings tagged under different CFDA numbers are not mixed into the $839,069,334.40.

The assistance-listing title is 21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT. CFDA 93.353 is the identifier. Combining 93.353 with broader NCI R01 or Cancer Centers codes would invent a combined cancer-research total this packet does not contain. Read the $839,069,334.40 as the obligation book tagged 93.353 only.

81 recipients in 31 jurisdictions

Eighty-one recipients share 168 awards, or about 2.1 award records per recipient on average. Splitting $839,069,334.40 evenly would assign about $10.4 million per recipient. That density is a research-center pattern: a moderate named-institution headcount carrying a couple of assistance rows each. The packet does not list the 81.

Thirty-one jurisdictions in the geographic count is a research-cluster map, not a nationwide formula. Moonshot dollars follow funded institutions, not equal shares across every state. Place-of-performance amounts are on the program table. Recipient count is organizational, not a census of oncologists or trial sites.

Award rows are not a trial census

Among HHS listings, 93.353 is a mid-row research file: 168 awards against 81 recipients. Award count is a weak proxy for “number of Moonshot projects” and a worse proxy for patients treated. Recipients (81) tell you how many named organizations sit on the extract; awards (168) tell you how many assistance rows were stored.

The packet does not report protocols, enrollment, or survival curves. Citing 168 as trials would be a unit error. Keep the units straight: dollars, awards, recipients, jurisdictions. The $839,069,334.40 stock is the obligation figure from USAspending.gov.

Obligations versus cancer-research outlays

The $839,069,334.40 is an obligation total from USAspending.gov. Outlays — cash paid against Beau Biden Cancer Moonshot awards — are not in the packet. A research file can show a large obligation stock while draws follow multi-year project periods. Deobligations and upward adjustments both move the total. A remaining-balance question is an outlay question this extract does not answer.

Use CFDA 93.353 to size this Cures Act cancer listing in the assistance file. Do not use it as an incidence dashboard. Those series live elsewhere. This page reports the obligation book tagged 93.353.

What the 93.353 tables omit

The program hub lists award-backed obligations from USAspending.gov. It is not a clinical-trial registry, not a cancer-registry extract, and not a drug-approval log. Series that never appear as assistance awards will not show up in the $839,069,334.40. That omission is definitional rather than a gap in the 168 award rows.

Place-of-performance on 31 jurisdictions is a coding field. Read the program page before treating those cells as equal shares of cancer research. Recipient dollars, if shown on the hub, are still obligation amounts, not cash already paid to research institutions.

Where the 93.353 table lives

The program page overlays these four facts. The all-programs index ranks 93.353 among other assistance listings. Agency pages show awarding-agency rollups that may include this CFDA among other HHS listings. For 93.353 only, start on the program page.

CFDA 93.353’s 168 awards spread $839,069,334.40 across 81 recipients and 31 jurisdictions. Quote award count as a record count, recipient count as the organizational headcount, and dollars as obligations from USAspending.gov. About 2.1 award records per recipient is the density story. Outlays remain a separate column. Source: USAspending.gov assistance awards.

A researcher comparing 93.353 with broader NCI R01 or Cancer Centers codes should keep CFDA numbers separate. The 81-recipient headcount on 31 jurisdictions is a research-cluster map, not a 50-state formula. Quote $839,069,334.40 as the USAspending obligation stock for the Beau Biden Cancer Moonshot only. About 2.1 award records per recipient is the density story on 168 awards. Trial enrollments, protocols, and survival curves remain outside the packet. Outlays are a separate column.

Questions

How much is obligated for the Beau Biden Cancer Moonshot?

USAspending.gov records $839,069,334.40 in obligations for CFDA 93.353. SpendingVault indexes 168 awards, 81 recipients, and 31 jurisdictions. The figure is an obligation sum from assistance awards, not an outlay and not a trial count. CFDA 93.353’s $839,069,334.40 is the USAspending obligation stock.

How many awards does CFDA 93.353 carry?

The listing shows 168 awards against 81 recipients, or about 2.1 award records per recipient. A simple average is about $4,994,460 per award. Award count is not a count of clinical trials or patients enrolled. Recipient dollars are on the program page.

How many organizations receive 93.353 awards?

The extract lists 81 recipients. Those are organizational recipients on assistance awards tagged 93.353, not a census of cancer centers. Geographic coding covers 31 jurisdictions. The packet does not name the 81 or publish enrollment figures. The packet reports obligations from USAspending.gov, not outlays.

Is $839,069,334.40 already paid for Moonshot research?

Not necessarily. Obligations are commitments. Outlays are payments. CFDA 93.353’s indexed total is the obligation stock from USAspending.gov. This page does not report cash drawn, remaining balances, or cancers prevented. The $839,069,334.40 on 168 awards is the obligation figure. The packet reports obligations from USAspending.gov, not outlays.